Aidi injection combined with CHOP chemotherapy regimen in the treatment of malignant lymphoma: A meta-analysis based on randomized controlled trials

Wang, Xiaoli; Jin, Wujun; Fang, Bingmu; Jiang, Jinhong; Liu, Min; Lan, Yifen; Qu, Zhigang; Ma, Guoyi; Yu, Jinming; Liu, Yonghua; Zeng, Yuxiao; Wang, Xiaoqiu

doi:10.4103/0973-1482.191619

Cited by 8 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aidi injection has demonstrated efficacy for a variety of cancers, such as lung cancer (14). Recently, its therapeutic effects on lymphoma have also been reported (12).…”

Section: Discussionmentioning

confidence: 99%

“…At present, the antitumor effects of A. membranaceus, A. senticosus, and cantharides are welldocumented (9)(10)(11). Additionally, lymphoma has been effectively treated by Aidi injection (12). Despite demonstrating efficacy, there are also many reports regarding adverse drug reactions (ADRs) caused by Chinese herbal preparations in recent years (13).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adverse drug reactions and nursing interventions in the treatment of non-Hodgkin’s lymphoma by Aidi injection

Liang¹,

Li²,

He³

et al. 2020

Ann Palliat Med

View full text Add to dashboard Cite

Background: To explore adverse drug reactions (ADRs) and the effects of nursing interventions after Aidi injection for the treatment of non-Hodgkin's lymphoma (NHL).Methods: A total of 104 NHL patients treated in our hospital from March 2019 to March 2020 were selected. All patients underwent conventional chemotherapy, with a concomitant Aidi injection administered at different doses (40, 60, 80, and 100 mL). ADRs were analyzed for all patients, and the clinical outcomes of ADRs were recorded after specific nursing interventions were performed.Results: A total of 17 NHL patients had ADRs, with a total incidence rate of 15.89% (total of 30 ADRs).In terms of different types of ADRs, inappetence accounted for the largest proportion, followed by skin pruritus and fever, phlebitis, nausea and vomiting, and chest distress and/or palpitation, the last of which shared the same proportion as chills and/or low fever and urticaria. The incidence rate of ADRs (total of 18 ADRs, 60.00%) was higher in NHL patients who were given 100 mL of Aidi injection. In terms of age and gender distribution of ADRs, there were 10 males (55.56%) and 7 females (44.44%), and ADRs were more common in patients aged 46-60 years old (total of 6 ADRs, 35.29%). Aidi injection mainly induced mild ADRs (total of 22 ADRs, 73.33%), and the resulting ADRs mostly occurred for <2 hours (total of 19 ADRs, 60.00%). After the specific nursing interventions were performed, no deaths due to ADRs occurred, and 12 (64.71%) cases were cured, 5 (29.41%) cases improved, and 1 (5.88%) case had no progression.Conclusions: Particular attention should be paid to ADRs in the treatment of NHL patients with Aidi injection. After ADRs occur, specific nursing interventions can aid in recovery and lead to improvements in prognosis.

show abstract

“…Aidi injection has demonstrated efficacy for a variety of cancers, such as lung cancer (14). Recently, its therapeutic effects on lymphoma have also been reported (12).…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Adverse drug reactions and nursing interventions in the treatment of non-Hodgkin’s lymphoma by Aidi injection

Liang¹,

Li²,

He³

et al. 2020

Ann Palliat Med

View full text Add to dashboard Cite

show abstract

“…Vincristine (O), on the other hand, binds to the protein tubulin and inhibits cell duplication; and prednisolone (P) is a corticosteroid [37]. The addition of rituximab, an anti-CD20 antibody, to the previous standard treatment, CHOP, enabled an increased response and OS [27].…”

Section: Inhibitorsmentioning

confidence: 99%

“…Doxorubicin (H) also found to play a key role in DNA damage by inserting itself between DNA bases which results in cell death [ 36 ]. Vincristine (O), on the other hand, binds to the protein tubulin and inhibits cell duplication; and prednisolone (P) is a corticosteroid [ 37 ]. The addition of rituximab, an anti‐CD20 antibody, to the previous standard treatment, CHOP, enabled an increased response and OS [ 27 ].…”

Section: Introductionmentioning

confidence: 99%

Mantle cell lymphoma treatment options for elderly/unfit patients: A systematic review

Till

Alnassfan

Cox-Pridmore

et al. 2021

eJHaem

View full text Add to dashboard Cite

Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin lymphoma (NHL) that is aggressive and incurable with existing therapies, presenting a significant unmet clinical need. MCL occurs mainly in elderly patients with comorbidities; thus, intense treatment options including allogeneic stem cell transplantation (Allo-SCT) are not feasible.New treatment options are emerging for this elderly/unfit treatment group, we therefore conducted a systematic review to determine whether they offered an advance on the existing recommended treatment, R-CHOP. The search strategies to identify MCL therapies were designed to capture the most relevant studies from 2013 to 2020.Following preferred reporting items for systematic reviews and meta-analyses and population,interventions, observations and study design analysis, R-CHOP, ibrutinib and bendamustine plus rituximab (BR) were taken forward for critical and statistical analysis. All three therapies were effective in increasing the overall survival (OS) and progression-free survival of elderly/unfit patients with MCL. However, none resulted in a significant increase in OS compared to R-CHOP. In addition, R-CHOP had a better toxicity profile when compared to both ibrutinib and BR. We therefore conclude that treatment of elderly/unfit patients with MCL is still a significant unmet clinical need; and suggest that outside of the clinical trial setting, R-CHOP should remain the recommended front-line treatment for this patient group.

show abstract

“…Aidi injection is an adjuvant TCM injection commonly used in treatment of lung cancer, 6 gastric cancer, 7 colorectal cancer, 8 liver cancer, 9 pancreatic cancer, 10 malignant lymphoma, 11 and esophageal cancer. 12 The ingredients of Aidi injection are extracts from Renshen (Radix Ginseng), Huangqi (Astragaloside), Ciwujia ( Eleutherococcus senticosus ), and Banmao (Cantharidin), all of which are important Chinese herbal medicines, with ability to inhibit cancers and improve immunity.…”

Section: Introductionmentioning

confidence: 99%

Aidi Injection, a Traditional Chinese Medicine Injection, Could Be Used as an Adjuvant Drug to Improve Quality of Life of Cancer Patients Receiving Chemotherapy: A Propensity Score Matching Analysis

et al. 2018

View full text Add to dashboard Cite

Background: Clinical research has paid increasing attention to quality of life (QoL) in recent years, but the assessment of QoL is difficult, hampered by the subjectivity, complexity, and adherence of patients and physicians. According to previous studies, QoL in cancer patients is related to performance status (PS) and influenced by chemotherapy-related toxicity. Aidi injection, a traditional Chinese medicine injection, is used as an adjuvant drug to enhance effectiveness of chemotherapy. The study aims to investigate whether Aidi injection could improve QoL by improving PS and reducing toxicity caused by chemotherapy. Methods: A retrospective cohort study was performed at the First Affiliated Hospital of Anhui Medicine University. Data of consecutive patients diagnosed with cancers between January 2014 and June 2017 were retrieved from the electronic medical record system. After a 1:1 propensity score match, patients were then divided into 2 groups based on the therapies used, that is, Aidi injection combined with chemotherapy and chemotherapy alone, and the PS, chemotherapy-related toxicity, and combined medication information were compared. The effect of different dosages of Aidi injection on patients was further explored. Results: A total of 3200 patients were included in this study. Aidi injection combined with chemotherapy exhibited significantly benefit in PS (P < .001, odds ratio [OR] 3.4, 95% confidence interval [CI] 2.4-4.8) compared with chemotherapy alone after adjusting for the factors that affect PS. The improvement rate of PS in the Aidi group was significantly higher than in the control group across the stratification of gender, age, tumor type, TNM stage, body mass index, nodal metastasis, prior chemotherapy, chemotherapy regimens, other Chinese tradition medicines, and chemotherapy cycle. Meanwhile, Aidi injection used synchronously with chemotherapeutic drugs could decrease the incident rate of damage to liver and kidney function, myelosuppression, and gastrointestinal reactions caused by chemotherapy. Conclusion: It was indicated that the integrative approach combining chemotherapy with Aidi injection, especially with the conventional dosage of Aidi injection, had significant benefit on QoL in cancer patients.

show abstract

Aidi injection combined with CHOP chemotherapy regimen in the treatment of malignant lymphoma: A meta-analysis based on randomized controlled trials

Abstract: With the present evidence, Aidi injection combined with CHOP chemotherapy regimen can improve the treatment response and quality of life and decrease the risk of developing severe leukopenia or thrombocytopenia.

Cited by 8 publications

References 0 publications

Adverse drug reactions and nursing interventions in the treatment of non-Hodgkin’s lymphoma by Aidi injection

Adverse drug reactions and nursing interventions in the treatment of non-Hodgkin’s lymphoma by Aidi injection

Mantle cell lymphoma treatment options for elderly/unfit patients: A systematic review

Aidi Injection, a Traditional Chinese Medicine Injection, Could Be Used as an Adjuvant Drug to Improve Quality of Life of Cancer Patients Receiving Chemotherapy: A Propensity Score Matching Analysis

Contact Info

Product

Resources

About